TAK-676

DRUG2 trials

Sponsors

Takeda, Presage Biosciences

Conditions

Carcinoma, Non-Small-Cell LungHead and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckTriple Negative Breast Neoplasms

Early Phase 1

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

CompletedNCT06062602

Presage BiosciencesHead and Neck Squamous Cell Carcinoma

Start: 2021-07-26End: 2022-11-15Updated: 2023-10-06

Phase 1

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

CompletedNCT04879849

TakedaCarcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms

Start: 2021-09-09End: 2024-04-30Updated: 2025-09-04

Related Papers

Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients.

2026-04-01

Data from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

2025-12-31

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

2025-12-01

Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors

Cancer Research2022-06-157 citations

Abstract 3448: The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models

Cancer Research2022-06-153 citations

Abstract CT243: Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN)

Cancer Research2022-06-152 citations

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-0118 citations

TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design.

Journal of Clinical Oncology2022-06-0117 citations